| Title |
Cannabidiol as a Potential Treatment for Anxiety Disorders
|
|---|---|
| Published in |
Neurotherapeutics, October 2015
|
| DOI | 10.1007/s13311-015-0387-1 |
| Pubmed ID | |
| Authors |
Esther M Blessing, Maria M Steenkamp, Jorge Manzanares, Charles R Marmar |
| Abstract |
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations. |
X Demographics
The data shown below were collected from the profiles of 221 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 68 | 31% |
| Canada | 14 | 6% |
| United Kingdom | 10 | 5% |
| Switzerland | 2 | <1% |
| Austria | 2 | <1% |
| Denmark | 2 | <1% |
| Portugal | 2 | <1% |
| Ireland | 2 | <1% |
| Brazil | 2 | <1% |
| Other | 13 | 6% |
| Unknown | 104 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 198 | 90% |
| Practitioners (doctors, other healthcare professionals) | 16 | 7% |
| Scientists | 4 | 2% |
| Science communicators (journalists, bloggers, editors) | 3 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,129 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Austria | 1 | <1% |
| Unknown | 1126 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 186 | 16% |
| Student > Master | 136 | 12% |
| Researcher | 126 | 11% |
| Student > Ph. D. Student | 104 | 9% |
| Other | 75 | 7% |
| Other | 160 | 14% |
| Unknown | 342 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 157 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 100 | 9% |
| Neuroscience | 94 | 8% |
| Agricultural and Biological Sciences | 77 | 7% |
| Psychology | 76 | 7% |
| Other | 248 | 22% |
| Unknown | 377 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2235. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2024.
All research outputs
#3,826
of 25,758,695 outputs
Outputs from Neurotherapeutics
#1
of 1,319 outputs
Outputs of similar age
#22
of 287,802 outputs
Outputs of similar age from Neurotherapeutics
#1
of 19 outputs
Altmetric has tracked 25,758,695 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,319 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,802 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.